Fuzuloparib

Fuzuloparib
Clinical data
Trade namesAiRuiYi
Other namesFluzoparib; SHR3162
Identifiers
  • 4-[[4-Fluoro-3-[2-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[1,5-a]pyrazine-7-carbonyl]phenyl]methyl]-2H-phthalazin-1-one
CAS Number
PubChem CID
DrugBank
UNII
ChEMBL
Chemical and physical data
FormulaC22H16F4N6O2
Molar mass472.404 g·mol−1
3D model (JSmol)
  • C1CN2C(=NC(=N2)C(F)(F)F)CN1C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F
  • InChI=InChI=1S/C22H16F4N6O2/c23-16-6-5-12(10-17-13-3-1-2-4-14(13)19(33)29-28-17)9-15(16)20(34)31-7-8-32-18(11-31)27-21(30-32)22(24,25)26/h1-6,9H,7-8,10-11H2,(H,29,33)
  • Key:XJGXCBHXFWBOTN-UHFFFAOYSA-N

Fuzuloparib (trade name AiRuiYi) is a pharmaceutical drug for the treatment of ovarian cancer.[1] It is approved for use in China.[2] It is an inhibitor of the poly (ADP-ribose) polymerase (PARP) enzyme.[3]

It is also being studied for its potential use for the treatment of pancreatic, breast, prostate, and lung cancer.[2]

References

  1. ^ Li N, Liu Q, Tian Y, Wu L (November 2022). "Overview of fuzuloparib in the treatment of ovarian cancer: background and future perspective". Journal of Gynecologic Oncology. 33 (6) e86. doi:10.3802/jgo.2022.33.e86. PMC 9634097. PMID 36335989.
  2. ^ a b Lee A (July 2021). "Fuzuloparib: First Approval". Drugs. 81 (10): 1221–1226. doi:10.1007/s40265-021-01541-x. PMC 8380563. PMID 34118019.
  3. ^ "Fuzuloparib - Jiangsu HengRui Medicine". AdisInsight. Springer Nature Switzerland AG.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.